Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors
{{output}}
The search for inhibitors of the Janus kinase family (JAK1, JAK2, JAK3 and TYK2) has been ongoing for several decades and has resulted in a number of JAK inhibitors being approved for use in patients, such as tofacitinib for the treatment of autoimmune disease... ...
